A suplementação diária com Saccharomyces boulardii THT 500101 exerce efeito renoprotetor e reduz espécies de bactérias patogênicas em modelo murino de diabetes
Data
2020-06-25
Autores
Abreu, Isabel Cristina Mallosto Emerich de [UNIFESP]
Orientadores
Uchiyama, Tatiana de Sousa da Cunha
Tipo
Tese de doutorado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
A disbiose intestinal é um fator de risco para o desenvolvimento e progressão da doença renal. O probiótico Saccharomyces boulardii (S. boulardii) pode agir secretando proteínas, modulando no hospedeiro vias de sinalização, respostas do sistema imune e processos inflamatórios. Assim, a suplementação com S. boulardii THT 500101 pode exercer efeito renoprotetor em modelo murino de diabetes. Para testar essa hipótese, trinta e seis camundongos machos C57BL/6 foram divididos em 4 grupos: controle (C), controle + probiotico (CP), diabetes (D), diabetes + probiotico (DP). O diabetes foi induzido por uma única injeção intraperitonial de estreptozotocina e o probiótico S. boulardii foi administrado por gavagem por 8 semanas. A administração crônica de S. boulardii reduziu significativamente a glicose sanguínea, a ingestão hídrica e o volume urinário do grupo DP comparado ao D. A albuminúria foi quatro vezes menor no DP quando comparado ao D e os efeitos positivos do probiótico também foram observados na glicosúria, proteinúria e ureia urinária. O diabetes aumentou a área glomerular e o probiótico foi capaz de aumentar a área do corpúsculo renal, favorecendo a função renal. A administração de S. boulardii restabeleceu a concentração de dopamina e aumentou o conteúdo de serotonina nos rins dos animais diabéticos. O probiótico também melhorou o balanço oxidativo e ativou o eixo vasodilatador do sistema renina-angiotensina (SRA). Além disso, o tratamento com S. boulardii reduziu a quantidade de espécies bacterianas consideradas biomarcadoras de nefropatia diabética (ND). A suplementação de S. boulardii tem efeito hipoglicemiante e antioxidante, agindo como moduladora do SRA renal, favorecendo a morfologia glomerular no contexto do diabetes e reduzindo poliúria, albuminuria e a quantidade de bactérias patogênicas nas fezes. Todos esses achados sugerem que a S. boulardii como um nova perspectiva terapêutica na ND.
Intestinal dysbiosis is a risk factor for the development or progression of renal disease. The probiotic Saccharomyces boulardii (S. boulardii) can act secreting proteins, modulating host signaling pathways, immune system responses, and inflammatory processes. Thus, we hypothesized that the supplementation of S. boulardii THT 500101 strain exerts a renoprotective effect in murine model of diabetes. To test this hypothesis, thirty-six C57BL/6 male mice were divided into four groups: control (C), control + probiotic (CP), diabetes (D), diabetes + probiotic (DP). Diabetes was induced by one intraperitoneal injection of streptozotocin and S. boulardii was administered by oral gavage for 8 weeks. Chronic administration of S. boulardii significantly reduced blood glucose, water intake, and urine volume of DP as compared with D. Albuminuria was four times lower in DP when compared to D and the positive effects of the probiotic were also observed in glycosuria, proteinuria, and urinary urea. Diabetes increased the glomerulus area and probiotic was capable of increasing the renal corpuscle area, favoring renal function. S. boulardii restored dopamine concentration and increased the content of serotonin in diabetic kidneys. The probiotic also improved the oxidative balance and activated the renin-angiotensin system (RAS) vasodilator axis. Furthermore, S. boulardii reduced population of bacterial species considered putative biomarkers of diabetic nephropathy (DN). S. boulardii has hypoglycemic and antioxidant effect acting as a renal RAS modulator, favoring glomerular morphology in the context of diabetes, reducing polyuria, albuminuria and pathogenic bacterium species on feces. All these findings suggest S. boulardii as a new approach to DN.
Intestinal dysbiosis is a risk factor for the development or progression of renal disease. The probiotic Saccharomyces boulardii (S. boulardii) can act secreting proteins, modulating host signaling pathways, immune system responses, and inflammatory processes. Thus, we hypothesized that the supplementation of S. boulardii THT 500101 strain exerts a renoprotective effect in murine model of diabetes. To test this hypothesis, thirty-six C57BL/6 male mice were divided into four groups: control (C), control + probiotic (CP), diabetes (D), diabetes + probiotic (DP). Diabetes was induced by one intraperitoneal injection of streptozotocin and S. boulardii was administered by oral gavage for 8 weeks. Chronic administration of S. boulardii significantly reduced blood glucose, water intake, and urine volume of DP as compared with D. Albuminuria was four times lower in DP when compared to D and the positive effects of the probiotic were also observed in glycosuria, proteinuria, and urinary urea. Diabetes increased the glomerulus area and probiotic was capable of increasing the renal corpuscle area, favoring renal function. S. boulardii restored dopamine concentration and increased the content of serotonin in diabetic kidneys. The probiotic also improved the oxidative balance and activated the renin-angiotensin system (RAS) vasodilator axis. Furthermore, S. boulardii reduced population of bacterial species considered putative biomarkers of diabetic nephropathy (DN). S. boulardii has hypoglycemic and antioxidant effect acting as a renal RAS modulator, favoring glomerular morphology in the context of diabetes, reducing polyuria, albuminuria and pathogenic bacterium species on feces. All these findings suggest S. boulardii as a new approach to DN.